echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Two major injections are about to be reviewed! 3.8 billion contrast agents, 1.4 billion anti-tumor drugs...

    Two major injections are about to be reviewed! 3.8 billion contrast agents, 1.4 billion anti-tumor drugs...

    • Last Update: 2020-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    June 12th, June 9, stone drug European-Italian pharmaceutical injection boron-timi, Shanghai State Taili Pharmaceutical iodized sea alcohol injection application changed to "in approval", both varieties are copied to 4 categories of declaration, once approved production will be treated as consistent evaluationAccording to The Net data, sales of boron-timizole and iodized sea alcohol injections in public medical institutions in China in 2019 were 1,442 million yuan and 3,837 million yuan, respectively.
    Table: Recently partially altered status-changing species boratizomi is a bipeptide-based borate analogue, the world's first synthetic new protease competitive inhibitor for use in the world for the treatment of multiple myeloma and set cell lymphomaDeveloped by Millennium Pharmaceuticals, Inc(acquired by Takeda), the product was approved by the FDA on May 13, 2003 and entered the Chinese market in 2005Takeda is currently responsible for sales in the U.Smarket, with sales of 118.3 billion yen in 2019, while Johnson and Johnson is responsible for sales outside the U.S., with sales of $751 million in 2019.
    Figure 1: Sales of boron-timizomi for injection in public medical institutions in China from 2015 to 2019 show that in recent years, sales of the terminals of domestic izede zomi for injection use in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as public medical institutions in China) have increased year by year, reaching 1.442 billion yuan in 2019, up 6.21% year-on-year.
    Figure 2: 2019 China's public medical institutions terminal injection boron-zomi manufacturers competition pattern The domestic market currently has 6 generic pharmaceutical enterprises and a former research and pharmaceutical enterprises have injection boron-to-zomi production approval, in 2019 China's public medical institutions terminal competition pattern, Xi'an Yangsen with 63.75 percent market share ranked first, is sunny, Haussen market share of more than 10%.
    Minet data show that the injection of boron-timizomi has not yet had an enterprise evaluation, Qilu, Howson, Zhengda Tianqing and other 5 pharmaceutical companies have submitted a supplementary application for consistency evaluation, are currently in the "in the review and approval (in the drug review center)";
    Iodine sea alcohol injection for X-ray contrast agent products, May 12, Hengrui announced, and Citli on the iodine sea alcohol injection and iodized paol injection signed a cooperation agreement, Hengrui will be responsible for the commercial operation of cooperative products in Chinese mainland, including marketing, self-self or co-marketing with distributorsIodine paol injections were approved for sale in May this year, and iody sea alcohol injections were also on the market.
    Figure 3: Sales of iodized sea alcohol injections at public medical institutions in China from 2015 to 2019 (units: 10,000 yuan) data show that the sales of iodized sea alcohol injections continued to grow at a good rate after the first time in 2017 when the sales of end-of-the-line sales of china's public medical institutions exceeded 3 billion yuan, reaching 3.837 billion yuan in 2019, up 3.52% Year-on-year.
    Figure 4: 2015-2019 China's public medical institutions terminal iodized sea alcohol injection TOP3 manufacturers the current market of iodine sea alcohol injection seisidic led by Yangzijiang, followed by General Electric and Beilu PharmaceuticalsYangzijiang submitted a supplementary application for product consistency evaluation in July 2019 and is currently in the "in the review and approval (in the drug review center), " Shanghai Division Taili exclusively with the new classification of the production, has now entered the "in the approval", is expected to be the first review.
    Source: Minnet database Note: statistics as of June 11, if there are omissions, welcome to point!
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.